trending Market Intelligence /marketintelligence/en/news-insights/trending/3gflo585tQkXrvoW4EXKUA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers Squibb seeks US FDA approval for blood cancer cell therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bristol-Myers Squibb seeks US FDA approval for blood cancer cell therapy

Bristol-Myers Squibb Co. filed an application with the U.S. Food and Drug Administration for the approval of its chimeric antigen receptor T cell therapy, dubbed liso-cel, to treat certain blood cancer patients.

The company's biologics license application seeks approval for liso-cel, or lisocabtagene maraleucel, to treat patients with large B-cell lymphoma, or LBCL, who have received at least two prior therapies and their disease either returned or did not respond to therapy.

Bristol-Myers' biologics license application is backed by data from the Transcend NHL 001 study, which evaluated the therapy in 269 patients with LBCL, including diffuse large B-cell lymphoma, or DLBCL.

The company presented results from multiple studies evaluating liso-cel at the 2019 American Society of Hematology's annual meeting earlier in December, with the results showing that a majority of patients responded to the therapy.

Bristol-Myers inherited liso-cel, which is yet to be approved for marketing in any country, after the $95 billion acquisition of Celgene Corp. If approved, liso-cel will compete with Yescarta from Gilead Sciences Inc. and Novartis AG's Kymriah, which are already approved.

Liso-cel has received multiple designations from the FDA, including breakthrough therapy and regenerative medicine advanced therapy designations for relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma, including DLBCL; primary mediastinal B-cell lymphoma; or Grade 3B follicular lymphoma.

The therapy is also in the European Medicines Agency's priority medicines scheme for relapsed/refractory DLBCL.